

Hemogenyx Pharmaceuticals plc 27 May 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:	HEMOGENYX PHARMACEUTICALS PLC		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)			
Non-UK issuer			
2. Reason for the notification (please mark the appropriate	e box or boxes with an "X")		
An acquisition or disposal of voting rights			
An acquisition or disposal of financial instruments			
An event changing the breakdown of voting rights			
Other (please specify) ⁱⁱⁱ :			
3. Details of person subject to the notification obligation	1 ^î ⁄		
Name	Craig Auringer		
City and country of registered office (if applicable) London, UK			
4. Full name of shareholder(s) (if different from 3.) ^v			
Name		_	



	egistered office (if appli				
5. Date on which the threshold was crossed or reached[√]:6. Date on which issuer notified (DD/MM/YYYY):			26/05/2020 27/05/2020		
	% of voting rights attached to shares (total of 8. A)	through instru	ing rights financial iments B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached	5.99			5.99	397,921,969
Position of previous notification (if applicable)	6.04			6.04	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached A: Voting rights attached to shares				
shares	Direct	Indirect	Direct	Indirect
ISIN code (if possible)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BYX3WZ24	23,837,250		5.99%	
SUBTOTAL 8. A	23,837,250		5.99	%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights



	SUBTOTAL 8. B 1	

Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period *	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights
	<u>'</u>		SUBTOTAL 8.B.2		

9. Information in relation to	o the person subject to the r	notification obligation (please	mark the	
applicable box with an "X")				
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}			•	Х
	,	iting rights and/or the ultimate controlling natural per	son or legal entity ^{xiv}	
Name [∞]	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it e or is higher than notifiable thresh	the



10. In case of proxy voting, please identify:		
Name of the proxy holder		
The number and % of voting rights held		
The date until which the voting rights will be held		
11. Additional information	on ^{xvi}	
Place of completion	London	
Date of completion	27/05/2020	